Floatz logo

Arimidex

Postmenopausal Women

University of PittsburghPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Postmenopausal Women cohort.

Asset / SponsorPhaseRating
Letrozole
Novartis Pharmaceuticals
Phase 2B
Everolimus
Novartis Pharmaceuticals
Phase 2B
FULVESTRANT
University of Pittsburgh
Phase 2CCC
Abt-301
University of Pittsburgh
Phase 2CCC
Tislelizumab
University of Pittsburgh
Phase 2CCC
PROPRANOLOL
Cairo University
N/AD

Same molecule, other indications

Arimidex is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative ·
73 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →